NMDAR antagonist MK-801 aggravates D1R-induced dyskinesias, while effectively reduces D2R-induced dyskinesias, the degree of which is of the same magnitude as the reduction of L-DOPA-induced dyskinesias (31). The gene discussed is DRD2; the disease is Dyskinesia.